ZP
IMPL

Zimmer Partners’s Impel Pharmaceuticals Inc. Common Stock IMPL Stock Holding History

Zimmer Partners’s Portfolio IMPL Stock Details IMPL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-25,000
Closed -$221K – 205
2021
Q2 		$221K Buy
+25,000
New +$299K ﹤0.01% 170

Other funds holding IMPL

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
NVPX
Norwest Venture Partners XIV Palo Alto, California $60.4M AUM 9.56% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LM
Lasry Marc $15.1M AUM 10.39% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Zimmer Partners's IMPL Position: Q3 2021 in Review

Zimmer Partners sold out of Impel Pharmaceuticals Inc. Common Stock (IMPL) in Q3 2021, closing a stake of 25,000 shares — an estimated $221K sold.

Zimmer Partners first reported a position in IMPL in Q2 2021 and held it in 1 quarter. The position peaked at $221K in Q2 2021. 44 funds tracked by Wall St. Rank hold IMPL as of Q3 2021.

  • Zimmer Partners reported no remaining Impel Pharmaceuticals Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Zimmer Partners sold 25,000 Impel Pharmaceuticals Inc. Common Stock shares in Q3 2021, an estimated $221K.
  • Zimmer Partners first reported a position in Impel Pharmaceuticals Inc. Common Stock in Q2 2021 and held it in 1 quarter.
  • Zimmer Partners's Impel Pharmaceuticals Inc. Common Stock position peaked at $221K in Q2 2021.
  • 44 funds tracked by Wall St. Rank held Impel Pharmaceuticals Inc. Common Stock as of Q3 2021.

Based on Zimmer Partners's 13F filing for Q3 2021, filed 15 Nov 2021.